- Home
- PAYO vs MNKD Comparison
PAYO vs MNKD Comparison
Compare PAYO & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAYO | MNKD |
|---|---|---|
| Founded | 2005 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | PAYO | MNKD |
|---|---|---|
| Price | $5.68 | $5.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $9.79 | ★ $10.08 |
| AVG Volume (30 Days) | 2.8M | ★ 3.1M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | ★ 0.18 | 0.10 |
| Revenue | ★ $1,039,820,000.00 | $313,787,000.00 |
| Revenue This Year | $11.18 | $21.54 |
| Revenue Next Year | $7.45 | $22.21 |
| P/E Ratio | ★ $31.18 | $58.48 |
| Revenue Growth | 10.58 | ★ 17.43 |
| 52 Week Low | $4.92 | $3.38 |
| 52 Week High | $11.19 | $7.07 |
Technical Indicators
Market Signals| Indicator | PAYO | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 62.91 |
| Support Level | $5.65 | $4.93 |
| Resistance Level | $5.87 | $5.10 |
| Average True Range (ATR) | 0.17 | 0.18 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 65.74 | 90.34 |
Price Performance
Historical ComparisonAbout PAYO Payoneer Global Inc.
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.